Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly

Seminars in Oncology

Volumn 30, Issue 1 SUPPL. 2, 2003, Pages 21-27

  Coiffier, Bertrand ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; PREDNISONE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STANDARD;

EID: 0037298412     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50021     Document Type: Conference Paper

References (31)

1. The non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
2. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993
3. DeVita VT, Canellos GP, Chabner B, et al: Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1:248-250, 1975
4. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
6. The Non-Hodgkin's Lymphoma Classification Project: Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 8:973-978, 1997
7. Armitage JO, Potter JF: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. J Am Geriatr Soc 32:269-273, 1984
8. Novitzky N, King HS, Johnson C, et al: Treatment of aggressive non-Hodgkin's lymphoma in the elderly. Am J Hematol 49:103-108, 1995
9. Tirelli U, Errante D, Van Glabbeke M, et al: CHOP is the standard regimen in patients ≥-70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Co-operative Study Group. J Clin Oncol 16:27-34, 1998
10. Coiffier B: What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:873-875, 1994
11. Sonneveld P, de Ridder M, van der Lelie H, et al: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530-2539, 1995
12. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
13. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
14. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
15. Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001
16. Wilson WH, Teruya-Feldstein J, Fest T, et al: Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601-609, 1997
17. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997
18. Hermine O, Haioun C, Lepage E, et al: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87:265-272, 1996
19. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
20. Wilson WH, Grossbard ML, Pittaluga S, et al: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 99:2685-2693, 2002
21. Wilson WH, Pittaluga S, O'Connor P, et al: Rituximab may overcome bcl-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas. Blood 98:343a, 2001 (suppl 1) (abstr)
22. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
23. Coiffier B, Lepage E, Gaulard P, et al: Prognostic factors affecting the efficacy of rituximab plus CHOP (R-CHOP) therapy in elderly patients with diffuse large B-cell lymphoma (DLCL): Results of a randomized GELA trial. Proc Am Soc Clin Oncol 20:283a, 2001 (abstr)
24. Davis TA, Grillo-López AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
25. Lopez A, Palacios C, Perez-Manga G, et al: Final results of a phase II study to evaluate the efficacy and safety of treatment and retreatment with rituximab in relapsed follicular or low-grade NHL. Blood 98:604a, 2001 (suppl 1) (abstr)
26. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
27. Philip T, Gomez F, Guglieimi C, et al: Long-term outcome of relapsed non-Hodgkin's lymphoma (NHL) patients included in the Parma trial: Incidence of late relapses, long-term toxicity and impact of the International Prognostic Index (IPI) at relapse. Proc Am Soc Clin Oncol 17:16a, 1998 (abstr)
28. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000
29. Kewalramani T, Zelenetz A, Bertino J, et al: Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Blood 98:436a, 2001 (suppl 1) (abstr)
30. Younes A, McLaughlin P, Hagemeister FB, et al: High response rate and complete remission rate achieved by adding rituximab to Taxol plus topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma. Blood 98:345a, 2001 (suppl 1) (abstr)
31. Jost LM, Jermann M, Stahel RA, et al: Rituximab-EPOCH-An effective salvage regime for relapsed, refractory, or transformed B-Cell lymphoma. Results of a phase II study. Proc Am Soc Clin Oncol 20:290a, 2001 (suppl 1) (abstr)